1021869-65-7

Upstream product

• 28395-03-1 Bumetanide 
• 530-62-1 1,1'-carbonyldiimidazole 

Downstream Products

• 1021869-53-3 C₂₃H₂₆N₄O₄S 
• 1021869-44-2 NTP-2024 
• 1021869-46-4 C₂₂H₃₀N₄O₄S 
• 1021869-52-2 C₂₃H₂₆N₄O₄S 
• 1021869-49-7 AqB₀₁₁ 
• 1021869-55-5 C₂₅H₃₇N₅O₄S 
• 1021869-51-1 3-butylamino-4-phenoxy-N-pyridin-4-yl-5-sulfamoylbenzamide 
• 1021869-47-5 C₂₃H₃₂N₄O₆S₂ 
• 1021869-45-3 C₂₄H₃₅N₅O₄S 
• 1021869-48-6 3-(butylamino)-N-(2-morpholinoethyl)-4-phenoxy-5-sulfamoylbenzamide 
• 1021869-50-0 C₂₂H₂₄N₄O₄S 
• 1021869-54-4 C₂₅H₃₈N₆O₄S 
• 1236290-60-0 (S)-α-methylbenzyl 3-aminosulfonyl-5-N-butylamino-4-phenoxybenzoate 
• 1236290-62-2 2-phenylethyl 3-aminosulfonyl-5-N-butylamino-4-phenoxybenzoate 

Relevant academic research and scientific papers

BUMETANIDE DERIVATIVES FOR THE THERAPY OF HYPERHIDROSIS

The present invention relates to bumetanide derivatives of formula (I) as well as pharmaceutical compositions comprising these compounds for use in the treatment or prevention of diseases/disorders involving Na+- K+- 2CI- - cotransporters (NKCCs), and particularly for use in the treatment or prevention of hyperhidrosis.

Experimental evaluation of proposed small-molecule inhibitors of water channel aquaporin-1

The aquaporin-1 (AQP1) water channel is a potentially important drug target, as AQP1 inhibition is predicted to have therapeutic action in edema, tumor growth, glaucoma, and other conditions. Here, we measured the AQP1 inhibition efficacy of 12 putative small-molecule AQP1 inhibitors reported in six recent studies, and one AQP1 activator. Osmotic water permeability was measured by stopped-flow light scattering in human and rat erythrocytes that natively express AQP1, in hemoglobin-free membrane vesicles from rat and human erythrocytes, and in plasma membrane vesicles isolated from AQP1-transfected Chinese hamster ovary cell cultures. As a positive control, 0.3 mM HgCl2 inhibited AQP1 water permeability by >95%. We found that none of the tested compounds at 50 μM significantly inhibited or increased AQP1 water permeability in these assays. Identification of AQP1 inhibitors remains an important priority.

BUMETANIDE, FUROSEMIDE, PIRETANIDE, AZOSEMIDE, AND TORSEMIDE ANALOGS, COMPOSITIONS AND METHODS OF USE

The present invention provides bumetanide, furosemide, piretanide, azosemide, and torsemide analogs and compositions comprising such analogs. The present invention also provides pharmaceutical compositions containing these bumetanide, furosemide, piretanide, azosemide, and torsemide analogs and methods for their use. All of these analogs are particularly useful for the treatment and/or prophylaxis of conditions that involve the Na+K+Cl- co-transporter or GABAA receptor including but not limited to addictive disorders, Alzheimer's Disease, anxiety disorders, ascites, autism, bipolar disorder, cancer, depression, endothelial corneal dystrophy, edema, epilepsy, glaucoma, Huntington's Disease, insomnia, ischemia, migraine, migraine with aura, neuropathic pain, nociceptive neuralgia, nociceptive pain, ocular diseases, pain, Parkinson's disease, personality disorders, postherpetic neuralgia, psychosis, schizophrenia, seizure disorders, tinnitus, and withdrawal syndromes.

AQUAPORIN MODULATORS AND METHODS OF USING THEM FOR THE TREATMENT OF EDEMA AND FLUID IMBALANCE

Compounds, including 3-carboxy aryl sulfonamide compounds, which agonize or antagonize aquaporin channels and methods of using them to treat disorders or diseases mediated by aquaporins.